1. Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM/TSP
- Author
-
Bárbara Brasil Santana, Maria Alice Freitas Queiroz, Rodrigo Arcoverde Cerveira, Claudia Mendonça Rodrigues, Ednelza da Silva Graça Amoras, Carlos Araújo da Costa, Maisa Silva de Sousa, Ricardo Ishak, Luiz Ricardo Goulart, and Antonio Carlos Rosário Vallinoto
- Subjects
Annexin A1 ,HTLV ,HAM/TSP ,Infection ,Biomarker ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Human T-lymphotropic virus 1 (HTLV-1) is etiologically associated with the chronic inflammatory neurodegenerative disease HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) Annexin A1 (AnxA1) is an anti-inflammatory protein with proposed neuroprotective and anti-neuroinflammatory functions. We hypothesized that ANXA1 gene expression may be dysregulated in HTLV-1-infected HAM/TSP patients. Methods This study involved 37 individuals infected with HTLV-1, including 21 asymptomatic (AS) carriers and 16 with HAM/TSP, and a control group of 30 individuals negative for HTLV-1 and HTLV-2. For AS HTLV-1-positive and HAM/TSP patients, ANXA1 and formyl peptide receptor (FPR1, FPR2 and FPR3) expression and HTLV-1 proviral load (PVL) in peripheral blood cells were evaluated by real-time quantitative PCR (qPCR), and plasma AnxA1 levels were determined by enzyme-linked immunosorbent assay (ELISA). Results ANXA1 gene expression was increased in the AS group compared with the HAM/TSP and control groups, but the differences were not statistically significant. FPR1 gene expression was higher in patients with HTLV-1 than in controls (AS, p = 0.0032; HAM/TSP, p
- Published
- 2021
- Full Text
- View/download PDF